Clinical Trial Update: Duodenal ReCET for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease [NA]

View source ↗

Summary

Clinical trial update for Duodenal ReCET evaluating its use in suboptimally controlled type 2 diabetes mellitus and metabolic dysfunction-associated steatotic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Metabolic Syndrome
• Type 2 Diabetes Mellitus

Drugs mentioned

• Duodenal ReCET

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | NA | Status: NOT_YET_RECRUITING